Blar i Fakultet for medisin og helsevitenskap (MH) på tidsskrift "Blood Cancer Journal"

Viser treff 1-7 av 7

    • Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin 

      Olsen, Oddrun Elise; Wader, Karin Fahl; Misund, Kristine; Våtsveen, Thea Kristin; Rø, Torstein Baade; Mylin, Anne K.; Turesson, I; Størdal, Berit Fladvad; Moen, Siv Helen; Standal, Therese; Waage, Anders; Sundan, Anders; Holien, Toril (Journal article; Peer reviewed, 2014)
      Multiple myeloma is a malignancy of plasma cells predominantly located in the bone marrow. A number of bone morphogenetic proteins (BMPs) induce apoptosis in myeloma cells in vitro, and with this study we add BMP-9 to the ...

    • BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis 

      Rustad, Even Holth; Dai, Hong Yan; Hov, Håkon; Coward, Eivind; Beisvag, Vidar; Myklebost, Ola; Hovig, Eivind; Nakken, Sigve; Vodak, Daniel; Meza-Zepeda, Leonardo A.; Sandvik, Arne Kristian; Wader, Karin Fahl; Misund, Kristine; Sundan, Anders; Aarset, Harald; Waage, Anders (Journal article; Peer reviewed, 2015)
      In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF ...

    • Germline variants at SOHLH2 influence multiple myeloma risk 

      Duran-Lozano, Laura; Thorleifsson, Gudmar; Lopez de Lapuente Portilla, Aitzkoa; Niroula, Abhishek; Went, Molly; Thodberg, Malte; Pertesi, Maroulio; Ajore, Ram; Cafaro, Caterina; Olason, P; Stefansdottir, Lilja; Bragi Walters, Walters; Halldorsson, Gisli H.; Turesson, Ingemar; Kaiser, Martin; Weinhold, Niels; Abildgaard, Niels; Andersen, Niels Frost; Mellqvist, Ulf-Henrik; Waage, Anders; Vangsted, Annette; Thorsteinsdottir, Unnur; Hansson, Markus; Houlston, Richard S.; Rafnar, Thorunn; Stefansson, Kari; Nilsson, Björn (Peer reviewed; Journal article, 2021)
      Multiple myeloma (MM) is caused by the uncontrolled, clonal expansion of plasma cells. While there is epidemiological evidence for inherited susceptibility, the molecular basis remains incompletely understood. We report a ...

    • Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells 

      Starheim, Kristian Kobbenes; Holien, Toril; Misund, Kristine; Johansson, Ida; Baranowska, Katarzyna Anna; Sponaas, Anne Marit; Hella, Hanne; Buene, Glenn; Waage, Anders; Sundan, Anders; Bjørkøy, Geir (Journal article; Peer reviewed, 2016)
      Multiple myeloma (myeloma in short) is an incurable cancer of antibody-producing plasma cells that comprise 13% of all hematological malignancies. The proteasome inhibitor bortezomib has improved treatment significantly, ...

    • Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report 

      Murray, David L.; Puig, Noemi; Kristinsson, Sigurður Y.; Usmani, Saad; Dispenzieri, Angela; Bianchi, Giada; Kumar, Shaji; Chng, Wee Joo; Hajek, Roman; Paiva, Bruno; Waage, Anders; Rajkumar, S. Vincent; Durie, Brian (Peer reviewed; Journal article, 2021)
      Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect ...

    • VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study 

      Nørgaard, Jakob Nordberg; Moore, Kari Lenita Falck; Slørdahl, Tobias Schmidt; Vik, Anders; Tvedt, Tor Henrik Anderson; Schjesvold, Fredrik (Journal article; Peer reviewed, 2024)
      Induction therapy followed by autologous stem cell transplantation (ASCT) is standard of care for young and fit patients with newly diagnosed multiple myeloma (MM) [1]. Induction therapy has evolved from doublet to triplet ...

    • Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group 

      Hillengass, J; Moulopoulos, LA; Delorme, S; Koutoulidis, V; Mosebach, J; Hielscher, T; Drake, M.; Rajkumar, SV; Oestergaard, B; Abildgaard, N; Hinge, M; Plesner, T; Suehara, Y; Matsue, K; Withofs, N; Caers, J; Waage, Anders; Goldschmidt, H; Dimopoulos, MA; Lentzsch, S; Durie, B; Terpos, E (Journal article; Peer reviewed, 2017)
      For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) has been implemented into the diagnostic criteria ...